Results 101 to 110 of about 1,892 (131)

Capability Development in the European Medicines Regulatory Network-A European Learning Needs Analysis and Survey Study. [PDF]

Clin Pharmacol Ther
Beard N, Kallio MJ, Kosec L, Westin UE, IncreaseNET consortium.   +4 more
europepmc   +1 more source

Protecting organ donation and transplantation programmes from regulatory uncertainty: an urgent appeal to the European Parliament, Council and Commission. [PDF]

Lancet Reg Health Eur
Cuende N, Izeta A, Domínguez-Gil B.
europepmc   +1 more source

Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024. [PDF]

BioDrugs
Almeida D, Mandslay D, Mol PGM, Sepodes B, Torre C.   +4 more
europepmc   +1 more source

Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit. [PDF]

Eur J Hosp Pharm
Bryla A, Lorent S, Vervacke A, Scolas G, Alexandre L.   +4 more
europepmc   +1 more source

Pharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review. [PDF]

Healthcare (Basel)
Serino M, Krstin M, Mucherino S, Menditto E, Orlando V.   +4 more
europepmc   +1 more source

Extracorporeal Photopheresis: Does It Have a Potential Place Among Cell-based Therapies? [PDF]

Transplant Direct
Parsonidis P, Wekerle T.
europepmc   +1 more source

The PRO-CAR-T™ study: achieving excellence in patient and public involvement and engagement. [PDF]

J Patient Rep Outcomes
Shaw KL, Hughes SE, Aiyegbusi OL, Ansell J, Chakera E, Chakraverty R, Chatterley M, Ferguson P, Khatsuria F, Lloyd R, McMullan C, Peipert JD, Pyatt L, Yarosh V, Calvert MJ.   +14 more
europepmc   +1 more source

Phase I clinical trials for cardiovascular diseases in Europe: analysis of trends, distribution, and regulatory context. [PDF]

Front Pharmacol
Grosdani S, Bertolani A, Reggiardo G, Cosentino N, Marenzi G, Agostoni P, Pompilio G, Pani A, Scatigna M.   +8 more
europepmc   +1 more source

Rebalancing innovation, affordability, and access for orphan drugs in the European Union. [PDF]

Lancet Reg Health Eur
Stevens H, Siotis G, Castanheira M, Dewatripont M, Akodad S, Daems S, Fischer A, Goldman M.   +7 more
europepmc   +1 more source

Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023. [PDF]

PLoS One
Bouwman L, Leufkens H, Sepodes B, Torre C.   +3 more
europepmc   +1 more source